India vs South-Eastern Asia: Proportion of the target population who received a 3rd dose of
India
95.0%
in 2024
South-Eastern Asia
56.0%
in 2024
India rank
28th
South-Eastern Asia rank
28th
Proportion of the target population who received a 3rd dose of over time
- India
- South-Eastern Asia
How they compare
India currently reports 95.0% against 56.0% in South-Eastern Asia, a difference of 39.0%.
That makes India's figure about 1.7 times South-Eastern Asia's.
The two have swapped places 1 time across 7 shared years of data; in 2018 it was South-Eastern Asia ahead.
India ranks 28th and South-Eastern Asia ranks 28th of 157 countries.
Across the 2 decades both report, India averaged higher in 1 and South-Eastern Asia in 1.
Head to head by decade
| Decade | India | South-Eastern Asia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 10.5% | 23.5% | 13.0% | South-Eastern Asia |
| 2020s | 58.0% | 35.6% | 22.4% | India |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received a 3rd dose of, India or South-Eastern Asia?
- India, at 95.0% against 56.0% in South-Eastern Asia as of 2024.
- What is the difference in proportion of the target population who received a 3rd dose of between India and South-Eastern Asia?
- 39.0%, with India ahead.
- How many years of comparable data are there for India and South-Eastern Asia?
- 7 years are reported by both, from 2018 to 2024.
- How do India and South-Eastern Asia rank globally for proportion of the target population who received a 3rd dose of?
- India ranks 28th and South-Eastern Asia ranks 28th of 157 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received a 3rd dose of pneumococcal conjugate (PCV3) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.